Economic Terms vs Control Terms: The Split Every Founder Misses in a Term Sheet
Emrah · Every clause in a term sheet falls into one of two buckets: who gets paid, and who gets to decide. Founders study the first bucket closely and skim the second, and that gap is where deals go wrong later.
The Story
Brad Feld and Jason Mendelson wrote what has become the closest thing the venture industry has to a standard manual on term sheets. Feld co-founded Foundry Group and has spent more than three decades as an early-stage investor. Mendelson practiced venture law before becoming his partner. Together they wrote Venture Deals: Be Smarter Than Your Lawyer and Venture Capitalist, a book built specifically to close the information gap between founders, who see a handful of term sheets in their careers, and the lawyers and investors on the other side of the table, who see hundreds.
The book's structure makes one argument before it explains a single clause. Chapter 3 opens with what the authors call the two key concepts behind any term sheet: economics and control. Everything that follows, they argue, is really just a variation on those two questions. Chapter 4 covers economic terms in detail: price, liquidation preference, pay to play provisions, vesting schedules, the option pool, and antidilution protection. Chapter 5 covers control terms: board composition, protective provisions, drag along rights, and conversion rights.
The split sounds obvious once it's named. In practice, almost every first-time founder negotiates as if only one of these two buckets exists.
The Idea
Economic terms answer a simple question: who gets what money, and when. Price determines what percentage of the company an investor buys. Liquidation preference determines who gets paid first, and how much, when the company is sold. Vesting determines how founder equity is earned over time. These terms are visible and countable. A founder can sit down with a spreadsheet and know exactly what a given valuation and dilution number means for their ownership.
Control terms answer a different question: who gets to decide things, and under what circumstances. Board composition determines who sits in the room when the company makes its biggest calls. Protective provisions list the decisions, often a raise, a sale, a large hire, a change to the budget, that require investor sign off before the company can act. Drag along rights let a defined majority of shareholders force everyone else to accept a sale, even shareholders who object.
Control terms are harder to price. There's no simple spreadsheet that converts "two board seats out of five" into a dollar figure the way a valuation number converts directly into ownership percentage. That's exactly why founders tend to skim past them during negotiation, and exactly why Feld and Mendelson spend an entire chapter insisting they shouldn't.
How Founders Should Read This
The practical mistake shows up in a specific and repeatable pattern. A founder heads into a raise with one clear goal: get the best price and keep dilution as low as possible. They spend hours with their lawyer modeling different valuation scenarios, comparing option pool sizes, checking how a participating versus non-participating liquidation preference changes their payout in different exit scenarios. All of that is real and worth doing.
Then the board seat clause comes up, and it gets a much shorter conversation. "Two investor seats, one founder seat, that's standard for this stage" is often where the discussion ends. The protective provisions list, usually an appendix full of dense legal language, gets even less attention. It looks like boilerplate. It reads like boilerplate. And in a company that never hits a rough patch, it might as well be boilerplate, because nobody ever needs to invoke it.
The trouble is that almost every company hits a rough patch eventually. Consider a founder who raises a Series A at a strong valuation, accepts a board with two investor seats and one founder seat, and signs off on a fairly standard protective provisions list that requires investor approval for new financing, a sale, and budget decisions above a certain threshold. Eighteen months later, growth slows. The board, using its majority, puts a CEO change on the table. The founder's ownership percentage on the cap table has not moved by a single point since the round closed. Their actual authority over the company has moved considerably.
Feld and Mendelson's advice is blunt: giving up a point or two of valuation is almost always cheaper than giving up board control or agreeing to an overly broad protective provisions list. A slightly lower price is fully recoverable in a future round if the company performs. A lost board seat, or a control structure that lets investors block your next move, is much harder to win back.
How Investors Should Read This
An investor evaluating the same term sheet is often running a mental trade between these two buckets, and fund economics explain why. A venture fund's returns are concentrated in a small number of companies that need to return the fund on their own, which means every portfolio company carries real downside risk for the fund as a whole. Control terms are the mechanism that protects that downside: a board seat and a solid protective provisions list give an investor real influence over a struggling company's direction, well before the company reaches a crisis. Because of this, an experienced investor will frequently accept a somewhat higher price if it comes packaged with a strong control position, and will negotiate hard on control even when the price is already generous to the founder.
This produces a useful signal during negotiation. A founder who pushes back on protective provisions, asks pointed questions about board composition, or negotiates the scope of what requires investor approval is showing that they understand what they're actually signing. A founder who only negotiates price is, from an investor's seat, a founder who hasn't fully read the document yet. That's not necessarily a dealbreaker on its own, but it's information an investor files away.
The real red flag runs the other direction. When a term sheet's protective provisions extend well past the standard list, reaching into routine operational decisions like hiring below the executive level or approving ordinary vendor contracts, that's no longer a normal control position. It's either a sign the investor doesn't trust the founder going in, or a sign the fund intends to run the company more actively than a typical board seat implies. Either reading is worth a direct conversation before signing.
Where the Two Views Collide
A founder's definition of a good round centers on price: high valuation, low dilution, a clean cap table. An investor's definition centers on control: enough board presence and enough protective provisions to manage downside if the company struggles. Both sides can walk away from the same signing believing they won, because they were optimizing for different lines in the same document.
The collision becomes visible only under stress, which is exactly why it's so easy to miss during a healthy, well-funded negotiation. A company growing on plan rarely tests its protective provisions or its board composition, so a founder who gave those terms away cheaply never notices the cost. It's only when growth slows, or a hard pivot is on the table, or an acquisition offer arrives that looks good to the board but underwhelming to the founder, that control terms determine who actually gets the final say. By then, renegotiating is no longer an option. The terms were set at signing.
The founders who navigate this well treat the term sheet as two separate negotiations happening in one document, not one. They know which points of leverage they have for price and which they have for control, and they don't spend all of their negotiating capital on the bucket that's easiest to understand.
The Takeaway
A term sheet with a great price and a weak control position can still leave a founder with less real say over their own company than a term sheet with a slightly lower price and a strong one. Before signing anything, read the board composition and protective provisions sections as carefully as the valuation line. That's the part of the document that decides what happens on the company's worst day, not its best one.
Source: Brad Feld & Jason Mendelson, "Venture Deals: Be Smarter Than Your Lawyer and Venture Capitalist," 4th Edition, 2019 — Wiley
